Skip to main content
Midas Edge

Aligos Therapeutics, Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

ALGS$2.57-34.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

(Unaudited, in thousands, except share and per share data)

Common Stock · AdditionalPaid-in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
SharesAmountCapitalDeficitIncomeEquity (Deficit)
Balance as of December 31, 20243,864,436$8$588,576$(618,008)$451$(28,973)
Issuance of common stock related to RSU vesting590-----
Issuance of common stock upon net exercise of pre-funded warrants146,468-----
Issuance of common stock, pre-funded warrants and common warrants in connection with 2025 PIPE offering2,103,3071105,003--105,004
Costs related to 2025 PIPE offering--(3,629)--(3,629)
Stock-based compensation expense related to employee stock awards--909--909
Stock-based compensation expense related to employee stock purchases--50--50
Other comprehensive loss----(4)(4)
Net income---43,088-43,088
Balance as of March 31, 20256,114,801$9$690,909$(574,920)$447$116,445
Issuance of common stock related to ESPP purchases36,473-180--180
Costs related to the PIPE offering--(29)--(29)
Stock-based compensation expense related to employee stock awards--1,050--1,050
Stock-based compensation expense related to employee stock purchases--110--110
Other comprehensive loss----(27)(27)
Net loss---(15,863)-(15,863)
Balance as of June 30, 20256,151,2749692,220(590,783)420101,866
Issuance of common stock related to RSU vesting2,233-2--2
Stock-based compensation expense related to employee stock awards--1,268--1,268
Stock-based compensation expense related to employee stock purchases--199--199
Other comprehensive gain----3535
Net loss---(31,537)-(31,537)
Balance as of September 30, 20256,153,5079693,689(622,320)45571,833

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited, in thousands, except share and per share data)

Common Stock · AdditionalPaid-in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
SharesAmountCapitalDeficitIncomeEquity
Balance as of December 31, 20233,003,855$7$578,325$(486,797)$545$92,080
Issuance of common stock upon exercise of pre-funded warrants22,771-----
Issuance of common stock from RSU vesting and settlement97-----
Stock-based compensation expense related to employee stock awards--2,500--2,500
Stock-based compensation expense related to employee stock purchases--148--148
Other comprehensive loss----(69)(69)
Net loss---(34,863)-(34,863)
Balance as of March 31, 20243,026,723$7$580,973$(521,660)$476$59,796
Issuance of common stock related to ESPP purchase22,438-297--297
Issuance of common stock upon exercise of pre-funded warrants142,2641---1
Stock-based compensation expense related to employee stock awards--1,918--1,918
Stock-based compensation expense related to employee stock purchases--138--138
Other comprehensive gain----1818
Net income---5,061-5,061
Balance as of June 30, 20243,191,425$8$583,326$(516,599)$494$67,229
Issuance of common stock upon exercise of pre-funded warrants128,578-----
Stock-based compensation expense related to employee stock awards4,777-1,904--1,904
Stock-based compensation expense related to employee stock purchases--139--139
Other comprehensive gain----8383
Net loss---(19,259)-(19,259)
Balance as of September 30, 20243,324,780$8$585,369$(535,858)$577$50,096
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.